Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Average Target - IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Evolution of the Target Price - IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

7d4ddebdf7cb67fc1dae.UwWIvQZJTPCNajHEsi4f2TuAG6gQiN7kxtjmsJcKB1g.FTXE60d8f7XSD3q9231x7WHtT5t38aiUh7LL_ONgXSJgf7D7VSEPm-odeA~2fde2d5daab73ab6fedaeb1e990663b3
Oct. 20 Jefferies Adjusts Price Target on IDEXX Laboratories to $705 From $795 MT
Oct. 16 JPMorgan Adjusts Price Target on IDEXX Laboratories to $750 From $775 MT
Oct. 12 KeyBanc Initiates IDEXX Laboratories at Sector Weight MT
Aug. 11 Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating MT
Aug. 05 Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792 MT
Aug. 05 Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650 MT
Aug. 05 UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating MT
Jul. 27 Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says MT
Jul. 27 UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating MT
Jul. 13 Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating MT
May. 06 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655 MT
May. 06 Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785 MT
Apr. 28 UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating MT
Apr. 27 Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating MT
Apr. 15 Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target MT
Apr. 14 Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating MT
Mar. 31 Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating MT
Feb. 09 Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating MT
Feb. 05 Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating MT
Feb. 04 Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 MT
Feb. 03 Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 MT
Feb. 03 UBS Adjusts IDEXX Laboratories PT to $730 From $750 MT
Feb. 03 Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785 MT
Feb. 03 BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 MT
Feb. 03 Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+24.56%
+14.41%
+18.06%
+9.65%
+19.16%
+11.51%
+17.34%
-1.68%
+29.13%
+29.97%
Average +17.21%
Weighted average by Cap. +15.47%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
560.38USD
Average target price
698.00USD
Spread / Average Target
+24.56%
High Price Target
805.00USD
Spread / Highest target
+43.65%
Low Price Target
470.00USD
Spread / Lowest Target
-16.13%

Analyst Consensus Detail

Analyst consensus - IDEXX Laboratories, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - IDEXX Laboratories, Inc.
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - IDEXX Laboratories, Inc.
  1. Stock Market
  2. Stocks
  3. IDXX Stock
  4. Consensus IDEXX Laboratories, Inc.